 A longitudinal, randomized, controlled, single-center Phase IV clinical trial will be performed to assess changes in bone mineral density BMD among voluntary apheresis blood donors. The primary outcome measure will be clinically significant decline in BMD at the lumbar spine assessed by dual-energy x-ray absorptiometry DXA. 